Vaxcyte, a preclinical biotech developing next-generation pneumococcal vaccines, raised $250 million by offering 15.6 million shares at $16, the high end of the range of $14 to $16. The company offered 1.6 million more shares than anticipated. At pricing, the company commands a fully diluted market value of $841 million.
Vaxcyte plans to list on the Nasdaq under the symbol PCVX. BofA Securities, Jefferies, and Evercore ISI acted as lead managers on the deal.
Vaccine biotech Vaxcyte prices upsized IPO at $16 high end
June 12, 2020

